Recce Pharmaceuticals Expands and accelerates clinical programs
- Recce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected over this year and next year
- The company expects to dose its first subject under a phase 1b/2a multi-dose and early-stage sepsis study later this year
- Meanwhile, new data from antoher phase one clinical trial of R327 supports findings from pre-clinical in-vivo kidney and UTI bacterial infection studies
- Furthermore, Recce has designed a new phase two study for R327 for treating diabetic foot ulcer infections, with the first patient to be dosed before the end of the year
- Shares in ReccePharmaceuticals are trading 6.15 per cent higher at 69 cents each at 2:59 pm AEST
